[December 18, 2014] |
|
Research and Markets: Cancer Pain - Pipeline Review, H1 2014
Research and Markets (http://www.researchandmarkets.com/research/m2sr8q/cancer_pain)
has announced the addition of the "Cancer
Pain - Pipeline Review, H1 2014" report to their offering.
This report provides comprehensive information on the therapeutic
development for Cancer Pain, complete with comparative analysis at
various stages, therapeutics assessment by drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type, along
with latest updates, and featured news and press releases. It also
reviews key players involved in the therapeutic development for Cancer
Pain and special features on late-stage and discontinued projects.
Drug profiles/records featured in the report undergoes periodic updation
following a stringent set of processes that ensures that all the
profiles are updated with the latest set of information. Additionally,
processes including live news & deals tracking, browser based alert-box
and clinical trials registries tracking ensure that the most recent
developments are captured on a real timebasis.
Reasons to buy
-
Provides strategically significant competitor information, analysis,
and insights to formulate effective R&D development strategies
-
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
-
Develop strategic initiatives by understanding the focus areas of
leading companies
-
Identify and understand important and diverse types of therapeutics
under development for Cancer Pain
-
Plan mergers and acquisitions effectively by identifying key players
of the most promising pipeline
-
Devise corrective measures for pipeline projects by understanding
Cancer Pain pipeline depth and focus of Indication therapeutics
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope
-
Modify the therapeutic portfolio by identifying discontinued projects
and understanding the factors that drove them from pipeline
Companies Mentioned:
-
Amgen
-
AstraZeneca
-
BioDelivery Sciences International
-
Nektar Therapeutics
-
Daiichi Sankyo Company
-
Egalet Corporation
-
Aphios Corporation
-
AcelRx Pharmaceuticals
-
Nippon Kayaku
-
Nippon Shinyaku
-
Orion
-
Pfizer
-
Zeria Pharmaceutical
-
GW Pharmaceuticals
-
IntelGenx
-
Benitec Biopharma
-
Kolon Life Science
-
Teikoku Seiyaku
-
BioAlliance Pharma
-
tesa Labtec
-
Colby Pharmaceutical
-
Grunenthal
-
AngioChem
-
WEX Pharmaceuticals
-
Virobay
-
QRxPharma
-
Winston Pharmaceuticals
-
Encore Therapeutics
-
Afferent Pharmaceuticals
-
Relevare Pharmaceuticals
-
Northern Light Pharmaceutical
For more information visit http://www.researchandmarkets.com/research/m2sr8q/cancer_pain
[ Back To TMCnet.com's Homepage ]
|